Stay updated on Telomelysin+Pembrolizumab in Esophagogastric Adenocarcinoma Clinical Trial

Sign up to get notified when there's something new on the Telomelysin+Pembrolizumab in Esophagogastric Adenocarcinoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Telomelysin+Pembrolizumab in Esophagogastric Adenocarcinoma Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    Added a Locations section listing Massachusetts, New York, and Pennsylvania as study sites; standalone entries for Massachusetts Locations, New York Locations, and Pennsylvania Locations were removed. Updated the page to revision v3.3.3 and removed the HHS Vulnerability Disclosure link.
    Difference
    0.4%
    Check dated 2025-12-24T13:51:46.000Z thumbnail image
  2. Check
    9 days ago
    No Change Detected
  3. Check
    17 days ago
    No Change Detected
  4. Check
    31 days ago
    Change Detected
    Summary
    Site revision updated from v3.2.0 to v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2025-11-25T13:35:31.000Z thumbnail image
  5. Check
    38 days ago
    Change Detected
    Summary
    Removed the government funding status notice from the page. All study details, eligibility criteria, locations, and study plan remain unchanged.
    Difference
    0.4%
    Check dated 2025-11-18T07:19:45.000Z thumbnail image
  6. Check
    52 days ago
    Change Detected
    Summary
    No notable differences were observed between the two screenshots; the study overview, inclusion/exclusion criteria, endpoints, and contact/location information appear unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.5%
    Check dated 2025-11-03T21:24:39.000Z thumbnail image
  7. Check
    81 days ago
    Change Detected
    Summary
    Added a government operating status notice and a v3.2.0 revision; removed the previous v3.1.0 revision. The page now communicates potential service delays and open NIH Clinical Center status, plus the updated software version.
    Difference
    3%
    Check dated 2025-10-06T05:59:48.000Z thumbnail image
  8. Check
    88 days ago
    Change Detected
    Summary
    Version updated from v3.0.2 to v3.1.0; the core identifier on the page has changed to reflect a newer release.
    Difference
    0.1%
    Check dated 2025-09-29T03:14:40.000Z thumbnail image

Stay in the know with updates to Telomelysin+Pembrolizumab in Esophagogastric Adenocarcinoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Telomelysin+Pembrolizumab in Esophagogastric Adenocarcinoma Clinical Trial page.